Displaying drugs 8926 - 8950 of 9162 in total
Anti-SARS-CoV-2 immunoglobulin
Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is obtained from the plasma of patients who recover from COVID-19 and develop neutralizing antibodies. Anti-coronavirus immunoglobulin is derived from COVID-19 convalescent plasma(https://go.drugbank.com/drugs/DB15692) but contains more SARS-CoV-2 neutralizing antibodies than found in convalescent plasma (https://go.drugbank.com/drugs/DB15692) as the antibodies are highly purified and concentrated.[L27521, L27526]
Investigational
Matched Description: … Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is obtained from the plasma of patients who recover …
Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media
Umbilical-cord derived MSCs are currently being tested for numerous clinical applications due to their immunosuppressive and anti-inflammatory properties. In comparison to bone-marrow derived MSCs, these cells are more resilient, easier to extract, and generally regarded as less immunogenic. The condition medium (CM) derived from these MSCs has also been implicated...
Investigational
Matched Description: … Many companies are creating their own version of this medium. ... One of these companies, Aspire, has created their own product, ACT-20 Conditioned Medium as a product …
MultiStem
MultiStem is an intravenously-administered, off-the-shelf proprietary product developed which comprises Multipotent Adult Progenitor Cells (MAPCs). Like mesenchymal stem cells, MAPCs are derived from bone-marrow stroma and are non-hematopoietically adherent. They have immunomodulatory and pro-angiogenic properties while also being mostly non-immunogenic. Additional benefits of MultiStem include their low immunogenicity, meaning they...
Investigational
Matched Description: … The cells for creation of the product are isolated from a qualified donor and expanded on a large scale ... Additional benefits of MultiStem include their low immunogenicity, meaning they can be administered without …
D-Glutamine
A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. It is the principal carrier of nitrogen in the body and is an important energy source for many cells.
Experimental
Matched Description: … It is the principal carrier of nitrogen in the body and is an important energy source for many cells. …
Zebularine
A chemically stable, cytidine analog that displays anti-tumor properties. It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates. Also shown to inhibit DNA methylation and tumor growth both in vitro and in vivo.
Experimental
Matched Description: … It acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as …
IR208
IR208 is a synthetic T-Cell receptor peptide
vaccine developed by Immune Response Corporation.
It contains three peptides (BV5S2, BV6S5
and BV13S1) expressed by T-Cells in over 90% of MS
patients. IR208 is currently undergoing Phase II
studies in a 200-patient trial.
Investigational
Matched Description: … It contains three peptides (BV5S2, BV6S5
and BV13S1) expressed by T-Cells in over 90% of MS
patients …
Pimagedine
Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease. It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies. It is beneficial in treating patients with diabetic nephropathy.
Investigational
Matched Description: … Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease …
IMC-1C11
IMC-1C11 is an anti-angiogenesis agent. It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma.
Investigational
Matched Description: … IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma. …
Selisistat
Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for SIRT1, SIRT2, SIRT3, HDAC and NADase respectively). Enhances p53 acetylation in response to DNA damaging agents.
Experimental
Matched Description: … Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase …
AdimrSC-2f
The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia . A phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548].
Investigational
Matched Description: … A phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548 …
PAC-113
PAC-113 an anti-fungal, for the treatment of oral candidiasis infections. It is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva. In vitro studies demonstrate that it has potent anti-fungal activity against the Candida albicans, including drug-resistant HIV patient isolates. PAC-113 is targeting oral...
Investigational
Matched Description: … PAC-113 an anti-fungal, for the treatment of oral candidiasis infections. …
Hexamethonium
A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by...
Experimental
Matched Description: … It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic …
Satraplatin
Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.
Investigational
Matched Description: … Satraplatin is a platinum compound that is currently under investigation as one treatment of patients …
EHT899
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Investigational
Matched Description: … EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune …
AdPEDF
AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal blood vessels to regress while protecting the eye’s photoreceptors.
Investigational
Matched Description: … AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). …
Masitinib
Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. It has been available in Europe since 2009, under the brand name Masivet. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
Investigational
Vet approved
Matched Description: … Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in dogs. …
Nadide
A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)
Experimental
Matched Description: … A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate …
Afimetoran
Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8.[L32018, L32023] It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants).
Investigational
Matched Description: … Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8. …
ABX1100
ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle. It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.
Investigational
Matched Description: … It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease …
FM-VP4
FM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors. FM-VP4 has been shown to inhibit cholesterol absorption and to lower plasma LDL-cholesterol and total cholesterol in a broad range of animal species. Additional experiments suggest that FM-VP4 can reduce plasma LDL...
Investigational
Matched Description: … inhibit cholesterol absorption and to lower plasma LDL-cholesterol and total cholesterol in a broad range of …
GC-373
GC-373 is a peptide aldehyde which is metabolized from the bisulfide adduct, GC-376 free acid[A219031,A219036]. It is an inhibitor of Mpro (otherwise known as 3CLpro), a viral encoded protease that cleaves and activates functional proteins involved in viral replication and transcription . GC-373 has been shown to inhibit the Mpro...
Experimental
Matched Description: … It is an inhibitor of Mpro (otherwise known as 3CLpro), a viral encoded protease ... The results showed potent inhibition of the target, suggesting that GC-373 holds therapeutic potential …
3-Acetylpyridine Adenine Dinucleotide
A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)
Experimental
Matched Description: … A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by …
Serelaxin
Recombinant human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic bones come together).It is a heterodimer protein secreted by the corpus luteum and placenta during pregnancy.
Investigational
Matched Description: … produced during pregnancy that facilitates the birth process by causing a softening and lengthening of …
Forodesine
Forodesine is a highly potent, orally active, rationally designed PNP inhibitor that has shown activity in preclinical studies with malignant cells and clinical utility against T-cell acute lymphoblastic leukemia and cutaneous T-cell lymphoma. Additional preliminary findings support its use for the management of some B-cell malignancies.
Investigational
Matched Description: … Additional preliminary findings support its use for the management of some B-cell malignancies. …
Maropitant
Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats.
Vet approved
Matched Description: … , is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of …
Displaying drugs 8926 - 8950 of 9162 in total